Abstract
MicroRNAs are short non-coding RNAs involved in critical biological processes. In the past decade, the deregulation of miRNAs has been well-documented in a wide range of human diseases, including cancer.
Overexpression and downregulation of miRNAs affect cellular pathways that contribute to carcinogenesis and tumor progression. This evidence makes miRNAs a suitable candidate for therapeutic applications and leads to developing strategies to manipulate their expression. Consistently, in vitro and in vivo studies show that Let-7, miR-10b, miR-21, miR-34, miR-155 and miR-221 are promising targets to develop miRNAs-based therapy for human malignancies. The purpose of this review is to discuss the different approaches that can be used to restore or reduce miRNAs expression in human cancer and the therapeutic implications.Keywords: AntimiRNAs, cancer therapy, Let-7, MiR-10b, MiR-155, MiR-21, MiR-221, MiR-34, miRNA mimics, miRNA therapeutic, tumor.
Graphical Abstract
MicroRNA
Title:MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
Volume: 6 Issue: 2
Author(s): Ramona Moles*
Affiliation:
- Department of Pathology and Laboratory Medicine, Center for Viral Oncology, University of Kansas Medical Center, Kansas City, KS, 66160,United States
Keywords: AntimiRNAs, cancer therapy, Let-7, MiR-10b, MiR-155, MiR-21, MiR-221, MiR-34, miRNA mimics, miRNA therapeutic, tumor.
Abstract: MicroRNAs are short non-coding RNAs involved in critical biological processes. In the past decade, the deregulation of miRNAs has been well-documented in a wide range of human diseases, including cancer.
Overexpression and downregulation of miRNAs affect cellular pathways that contribute to carcinogenesis and tumor progression. This evidence makes miRNAs a suitable candidate for therapeutic applications and leads to developing strategies to manipulate their expression. Consistently, in vitro and in vivo studies show that Let-7, miR-10b, miR-21, miR-34, miR-155 and miR-221 are promising targets to develop miRNAs-based therapy for human malignancies. The purpose of this review is to discuss the different approaches that can be used to restore or reduce miRNAs expression in human cancer and the therapeutic implications.Export Options
About this article
Cite this article as:
Moles Ramona *, MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment, MicroRNA 2017; 6 (2) . https://dx.doi.org/10.2174/2211536606666170710183039
DOI https://dx.doi.org/10.2174/2211536606666170710183039 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface [Hot Topic: Chromogranin A and Its Derived Peptides as Potential Regulators of Immune, Endocrine and Metabolic Systems - In Search of Its Physiological Role (Guest Editors: K.B. Helle and G. Serck-Hanssen)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Obesity and Coronary Microvascular Disease – Implications for Adipose Tissue-Mediated Remote Inflammatory Response
Current Vascular Pharmacology Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry General Anesthetics in Pediatric Anesthesia: Influences on the Developing Brain
Current Drug Targets Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Current Medicinal Chemistry Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents The Pathobiology of Endothelin-1 in Vein Graft Disease: Are ETA Receptor Antagonists the Solution to Prevent Vein Graft Failure?
Current Vascular Pharmacology Modulation of Huntington’s Disease in Drosophila
CNS & Neurological Disorders - Drug Targets Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Reactive Oxygen Production Induced by the Gut Microbiota: Pharmacotherapeutic Implications
Current Medicinal Chemistry Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Perinatal Management of Fetal Tumors
Current Pediatric Reviews Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery